uniQure N.V., a biopharmaceutical company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company offers Glybera, a gene therapy product for the treatment of patients with lipoprotein lipase
This is not a pick of mine I had only used it and CDE for the contest. I wish had played them as they both went up especially CDE.
uniQure Announces Hemophilia B Gene Therapy Program To Enter Pivotal Study With FIX-Padua Variant in 2018 https://finance.yahoo.com/news/uniqure-announces-hemophilia-b-gene-110000602.html
Cowen Shines Light on Uniqure NV (QURE) as the Latter Advances Padua Variant AMT-061 into Phase 3 QURE investors are overwhelmingly excited today after the drug maker announced advancement of AMT-061, a Padua variant FIX AAV5 gene therapy, in hemophilia B, into a pivotal phase 3 trial in 3Q18.
uniQure Announces Proposed Public Offering https://finance.yahoo.com/news/uniqure-announces-proposed-public-offering-200628861.html
uniQure Announces Pricing of its Public Offering >> "...the pricing of its underwritten public offering of 5,000,000 of its ordinary shares at a public offering price of $18.25 per share..." https://finance.yahoo.com/news/uniqure-announces-pricing-public-offering-001448837.html